Also known as: Uzedy, UZEDY
Uzedy is a long-acting subcutaneous injectable formulation of risperidone approved for treatment of schizophrenia in adults. It offers monthly or every-two-month dosing schedules after oral risperidone tolerability has been established. FDA approved Uzedy in 2023.
Teva said the FDA accepted its New Drug Application for long-acting olanzapine for schizophrenia, with a decision expected later this year. The company also reported Austedo sales of $2.26 billion in 2025 and plans six biosimilar launches in 2026 and 2027.
Researchers identify speech latency as a biomarker to enrich schizophrenia clinical trials, while a separate study finds clozapine more effective than alternatives for patients who fail initial antipsychotic treatment.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
